Full Text | PDF

Share on facebook Share on tweeters Share on linkedin Share on googleplus

Int J Med Sci 2017; 14(2):102-109. doi:10.7150/ijms.17025 This issue Cite

Research Paper

Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015

Toshinobu Matsui1, Ryogo Umetsu1,2, Yamato Kato1, Yuuki Hane1, Sayaka Sasaoka1, Yumi Motooka1, Haruna Hatahira1, Junko Abe1,3, Akiho Fukuda1, Misa Naganuma1, Yasutomi Kinosada4, Mitsuhiro Nakamura1✉

1. Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan;
2. Clinical Research, Innovation and Education Center, Tohoku University Hospital, 1-1, Seiryomachi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan;
3. Medical Database Co., LTD, 3-11-10 Higashi, Shibuya-ku, Tokyo, 150-0011, Japan;
4. United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.

✉ Corresponding author: Mitsuhiro Nakamura, Ph.D. Professor, Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4, Daigaku-nishi, Gifu, 501-1196, JAPAN, Tel: +81-58-230-8100, Fax: +81-58-230-8105, E-mail: mnakamuraac.jp.

Citation:
Matsui T, Umetsu R, Kato Y, Hane Y, Sasaoka S, Motooka Y, Hatahira H, Abe J, Fukuda A, Naganuma M, Kinosada Y, Nakamura M. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. Int J Med Sci 2017; 14(2):102-109. doi:10.7150/ijms.17025. https://www.medsci.org/v14p0102.htm
Other styles

File import instruction

Abstract

Tumor necrosis factor-α (TNF-α) inhibitors are increasingly being used as treatment for rheumatoid arthritis (RA). However, the administration of these drugs carries the risk of inducing injection site reaction (ISR). ISR gives rise to patient stress, nervousness, and a decrease in quality of life (QoL). In order to alleviate pain and other symptoms, early countermeasures must be taken against this adverse event. In order to improve understanding of the risk factors contributing to the induction of ISR, we evaluated the association between TNF-α inhibitors and ISR by applying a logistic regression model to age-stratified data obtained from the Food and Drug Administration Adverse Event Reporting System (FAERS) database.

The FAERS database contains 7,561,254 reports from January 2004 to December 2015. Adjusted reporting odds ratios (RORs) (95% Confidence Intervals) were obtained for interaction terms for age-stratified groups treated with etanercept (ETN) and adalimumab (ADA). The adjusted RORs for ETN* ≥ 70 and ADA* ≥ 70 groups were the lowest among the age-stratified groups undergoing the respective monotherapies. Furthermore, we found that crude RORs for ETN + methotrexate (MTX) combination therapy and ADA + MTX combination therapy were lower than those for the respective monotherapies.

This study was the first to evaluate the relationship between aging and ISR using the FAERS database.

Keywords: etanercept, adalimumab, injection site reaction, adverse event reporting system.

Citation styles

APA
Matsui, T., Umetsu, R., Kato, Y., Hane, Y., Sasaoka, S., Motooka, Y., Hatahira, H., Abe, J., Fukuda, A., Naganuma, M., Kinosada, Y., Nakamura, M. (2017). Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. International Journal of Medical Sciences, 14(2), 102-109. https://doi.org/10.7150/ijms.17025.

ACS
Matsui, T.; Umetsu, R.; Kato, Y.; Hane, Y.; Sasaoka, S.; Motooka, Y.; Hatahira, H.; Abe, J.; Fukuda, A.; Naganuma, M.; Kinosada, Y.; Nakamura, M. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. Int. J. Med. Sci. 2017, 14 (2), 102-109. DOI: 10.7150/ijms.17025.

NLM
Matsui T, Umetsu R, Kato Y, Hane Y, Sasaoka S, Motooka Y, Hatahira H, Abe J, Fukuda A, Naganuma M, Kinosada Y, Nakamura M. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. Int J Med Sci 2017; 14(2):102-109. doi:10.7150/ijms.17025. https://www.medsci.org/v14p0102.htm

CSE
Matsui T, Umetsu R, Kato Y, Hane Y, Sasaoka S, Motooka Y, Hatahira H, Abe J, Fukuda A, Naganuma M, Kinosada Y, Nakamura M. 2017. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. Int J Med Sci. 14(2):102-109.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2025 Ivyspring International Publisher. Terms of use